Abstract:3271 Genetic losses affecting the short arm of chromosome 8 are frequent events in the development of medulloblastoma (MB), the most common malignant brain tumor of childhood, and suggest the presence of critical tumor suppressor gene(s) (TSGs) in this region. To map critical regions of genetic loss on 8p in MB, we performed loss of heterozygosity (LOH) analysis using a panel of 23 polymorphic microsatellite makers, in 30 primary medulloblastoma and 11 MB cell lines. LOH on 8p was found in 26% of cases and a 1.6Mb common region of genetic loss was identified at 8p23.1, defined by polymorphic markers D8S520 and D8S1130. Among the genes contained in this region, GATA4 (encoding the transcription factor, GATA binding protein 4) has recently been found to be hypermethylated and epigenetically silenced in other cancer types, and thus represents a promising candidate TSG at 8p23.1. We therefore assessed the promoter hypermethylation and transcript expression status of GATA4 in MB. Evidence of GATA4 promoter hypermethylation was found in 2 of 11 MB cell lines, following bisulphite treatment and methylation specific PCR (MSP) analysis. Reduced GATA4 transcript levels were observed in both cell lines, which were restored following treatment with the DNA methyltransferase inhibitor, 5-aza-2’deoxycytidine (5azaCdR), indicating that GATA4 promoter hypermethylation in MB cell lines is associated with its methylation-dependent transcriptional silencing. However, no consistent evidence of GATA4 hypermethylation was found in a cohort of 27 primary MBs. In another cell line, the GATA4 transcript was absent, but its expression was unaffected by 5azaCdR treatment, indicating a potential role for methylation-independent mechanisms of GATA4 silencing in MB. Based on these data, promoter hypermethylation of GATA4 is unlikely to play a major role in MB development. However, a methylation-independent mechanism of GATA4 inactivation cannot be excluded. Extensive analysis of GATA4 genetic mutation and deletion are therefore currently ongoing in our primary tumour panel, to investigate further its role as a candidate TSG at 8p23.1 in MB.

Analysis of loss of heterozygosity on chromosomes 10q, 11, and 16 in medulloblastomas

Identification of a Novel Homozygous Deletion Region at 6q23.1 in Medulloblastomas Using High-Resolution Array Comparative Genomic Hybridization Analysis

Quantitative Proteomic Analysis of Oligodendrogliomas with and Without 1p/19q Deletion

Loss of Heterozygosity on Chromosome 3p in Breast Cancer and Precancerous Lesion

Identification of A Minimal Region of Genetic Loss at 8p23.1 and Investigation of Gata4 As A Candidate Tumor Suppressor Gene in Medulloblastoma

Amplification and Overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8Q24.22-Q24.23 in Medulloblastoma

Detection of Chromosomal DNA Imbalance in Medulloblastoma by Comparative Genomic Hybridization

SEARCH AND LOCATION OF ALLELE LOSS IN HEMATOLOGICALMALIGNANT DISEASES BY MICROSATELLITES

Chromosome 10q may harbor several tumor supppressor genes in gl ioblastomas

[Loss of Heterozygosity Analysis to Define Putative Region Involved in Tumor Differentiation and Metastases in Sporadic Colorectal Cancer Patients].

Mutation Analysis Of Dmbt1 In Glioblastoma, Medulloblastoma And Oligodendroglial Tumors

Chromosome 10 May Harbor Multiple Novel Tumor Suppressor Genes Associated with Glioblastoma

Detailed Deletion Mapping of Loss of Heterozygosity on 22q13 in Sporadic Colorectal Cancer

Allelic Deletion Analyses of MMAC/PTEN and DMBT1 Loci in Gliomas: Relationship to Prognostic Significance.

[An Allelotype Study of Human Glioblastoma].

[Refined Mapping of Loss of Heterzygosity on 10Q23-24 in Sporadic Colorectal Carcinoma].

Refined Mapping of Loss of Heterzygosity on Chromosome 1 in Sporadic Colorectal Carcinoma

Molecular analysis of PinX1 in medulloblastomas.

Loss of Heterozygosity on Chromosome 3p in Thyroid Tumors

Refined Mapping of Loss of Heterozygosity on 1Q31.1-32.1 in Sporadic Colorectal Carcinoma

Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature That Correlates With Poor Outcomes in Patients With Medulloblastoma